Brendan M. Everett

11.4k citations

91 papers · 5.2k indexed · 3 hit papers · h-index 36

Impact in

Cardiology and Cardiovascular Medicine top 0.5%
- Cardiovascular Function and Risk Factors
- Acute Myocardial Infarction Research
- Heart Failure Treatment and Management
Endocrinology, Diabetes and Metabolism top 0.5%
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Management and Research

Papers in

Endocrinology, Diabetes and Metabolism 39
- Diabetes Treatment and Management 28
- Diabetes Management and Research 13
- Diabetes, Cardiovascular Risks, and Lipoproteins 10
Cardiology and Cardiovascular Medicine 37
- Acute Myocardial Infarction Research 14
- Cardiovascular Function and Risk Factors 11

Co-authors: Paul M. Ridker Robert J. Glynn Peter Libby Julie E. Buring Jean MacFadyen Nancy R. Cook Aruna D. Pradhan Tom Thurén
Journals: Circulation (9 papers)Journal of the American College of Cardiology (7 papers)Clinical Chemistry (5 papers)American Heart Journal (4 papers)Arthritis Care & Research (4 papers)
Partner nations: United States Switzerland Germany

In The Last Decade

Brendan M. Everett

91 papers receiving 5.1k citations

Hit Papers

align trajectories log scale

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes 2020 · 292 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Journal of the American College of Cardiology
2019 Circulation
2013 Circulation

Peers

Countries citing papers authored by Brendan M. Everett

Since Specialization

Citations

This map shows the geographic impact of Brendan M. Everett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendan M. Everett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendan M. Everett more than expected).

Fields of papers citing papers by Brendan M. Everett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brendan M. Everett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendan M. Everett. The network helps show where Brendan M. Everett may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Brendan M. Everett, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brendan M. Everett Line = papers co-authored together Brendan M. Everett links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Expanding the triglyceride range in clinical trials: therapeutic opportunities European Heart Journal ·Ask Tybjærg Nordestgaard, Aruna D. Pradhan, Brendan M. Everett, Jean MacFadyen, Deepak L. Bhatt, Frank L.J. Visseren, Peter Libby, Raul D. Santos, Steven E. Nissen, Børge G. Nordestgaard, Paul M. Ridker	2025	6
2	Effectiveness and safety of empagliflozin: final results from the EMPRISE study Diabetologia ·周慧霞, Helen Tesfaye, Sebastian Schneeweiß, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, M. Weinelt, Anouk Déruaz‐Luyet, Julie M. Paik, Elisabetta Patorno	2024	8
3	Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study Cardiovascular Diabetology ·周慧霞, Helen Tesfaye, Sebastian Schneeweiß, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, M. Weinelt, Anouk Déruaz‐Luyet, Julie M. Paik, Elisabetta Patorno	2024	14
4	Sodium–glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study European Heart Journal ·Edouard L. Fu, Elisabetta Patorno, Brendan M. Everett, Muthiah Vaduganathan, Scott D. Solomon, Raisa Levin, Sebastian Schneeweiß, Rishi Desai	2023	19
5	Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care American Heart Journal ·Rishi Desai, Robert J. Glynn, Brendan M. Everett, Sebastian Schneeweiß, Deborah J. Wexler, Lily G. Bessette, Anouk Déruaz‐Luyet, Ola Vedin, Kimberly G. Brodovicz, Elisabetta Patorno	2022	12
6	Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Annals of Internal Medicine ·Elisabetta Patorno, 周慧霞, Robert J. Glynn, Sebastian Schneeweiß, Deborah J. Wexler, Llc Page Ayers Cowley Architects, Lily G. Bessette, Kristyn Chin, Brendan M. Everett, Seoyoung C. Kim	2021	65
7	Comparative Risks of Cardiovascular Disease in Patients With Systemic Lupus Erythematosus, Diabetes Mellitus, and in General Medicaid Recipients Arthritis Care & Research ·Medha Barbhaiya, Candace H. Feldman, Jonathan Fisher, Hongshu Guan, Michael A. Fischer, Brendan M. Everett, Karen H. Costenbader	2020	36
8	Medicaid Expansion and Utilization of Antihyperglycemic Therapies Diabetes Care ·Andrew Sumarsono, Leo F. Buckley, Edward Bohres, Rishi K. Wadhera, Haider J. Warraich, Rishi Desai, Brendan M. Everett, Darren K. McGuire, Gregg C. Fonarow, Javed Butler, Ambarish Pandey, Muthiah Vaduganathan	2020	15
9	Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial Journal of the American College of Cardiology ·Brendan M. Everett, Jean MacFadyen, Tom Thurén, Peter Libby, Robert J. Glynn, Paul M. Ridker	2020	139
10	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure Circulation ·Brendan M. Everett, Jan H. Cornel, Mitja Lainščak, Stefan D. Anker, Antonio Abbate, Tom Thurén, Peter Libby, Robert J. Glynn, Paul M. Ridker Hit paper breakdown →	2019	458
11	Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores Rheumatology International ·Cameron B. Speyer, Daniel Li, Hongshu Guan, Kazuki Yoshida, Emma Stevens, April Jorge, Brendan M. Everett, Candace H. Feldman, Karen H. Costenbader	2019	21
12	Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population Arthritis Care & Research ·Jonathan Fisher, Medha Barbhaiya, Michael A. Fischer, Hongshu Guan, Tzu‐Chieh Lin, Candace H. Feldman, Brendan M. Everett, Karen H. Costenbader	2018	14
13	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Journal of the American College of Cardiology ·Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, Jenifer M. Brown, William T. Cefalu, James L. Januzzi, Rita R. Kalyani, Mikhail Kosiborod, Melissa Magwire, Pamela B. Morris, Laurence Sperling	2018	203
14	Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations The American Journal of Cardiology ·Pratyaksh K. Srivastava, Aruna D. Pradhan, Nancy R. Cook, Paul M. Ridker, Brendan M. Everett	2015	9
15	Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes New England Journal of Medicine ·Brendan M. Everett, Maria M. Brooks, Helen Vlachos, Bernard Chaitman, Robert L. Frye, Deepak L. Bhatt	2015	180
16	Novel genetic markers improve measures of atrial fibrillation risk prediction European Heart Journal ·Brendan M. Everett, Nancy R. Cook, David Conen, Daniel I. Chasman, Paul M. Ridker, Christine M. Albert	2013	91
17	Smoking, Smoking Cessation and Risk of Symptomatic Peripheral Artery Disease in Women: A Prospective Study Annals of Internal Medicine ·David Conen, Brendan M. Everett, Tobias Kurth, Mark A. Creager, Julie E. Buring, Paul M. Ridker, Aruna D. Pradhan	2011	4
18	Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes JAMA ·Aruna D. Pradhan, Brendan M. Everett, Nancy R. Cook, Nader Rifai, Paul M. Ridker	2009	100
19	The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women Journal of the American College of Cardiology ·Brendan M. Everett, Tobias Kurth, Julie E. Buring, Paul M. Ridker	2006	106
20	Predictors for the Development of Elevated Anti-Heparin/Platelet Factor 4 Antibody Titers in Patients Undergoing Cardiac Catheterization The American Journal of Cardiology ·Robert W. Yeh, Brendan M. Everett, César Casrolli, David J. Dorer, Michael Laposata, Elizabeth M. Van Cott, Ik–Kyung Jang	2006	2

About Brendan M. Everett

Brendan M. Everett is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Internal Medicine, Rheumatology and Immunology, having authored 91 papers that have together received 5.2k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (28 papers), Lipoproteins and Cardiovascular Health (16 papers), Acute Myocardial Infarction Research (14 papers), Diabetes Management and Research (13 papers), Systemic Lupus Erythematosus Research (12 papers), Atherosclerosis and Cardiovascular Diseases (12 papers), Cardiovascular Function and Risk Factors (11 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (2.2k citations), Endocrinology, Diabetes and Metabolism (1.6k citations), Surgery (1.6k citations), Internal Medicine (123 citations) and Immunology (686 citations). Brendan M. Everett has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Paul M. Ridker, Robert J. Glynn, Peter Libby, Julie E. Buring, Jean MacFadyen, Nancy R. Cook, Aruna D. Pradhan, Tom Thurén, Christine M. Albert and Tobias Kurth. Their work appears in journals such as Circulation, Journal of the American College of Cardiology, Clinical Chemistry, American Heart Journal and Arthritis Care & Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact